Valeur202020212022202320242025TTMFlux de trésorerie liés aux activités d'investissement-2.87 M-433 K-100 K-808 K-757 K-1.37 M-1.27 MFlux de trésorerie liés aux activités de financement149.55 M274 K194.12 M6.77 M587 K276.18 M365.08 MFlux de trésorerie disponible-165.61 M-108.24 M-55.67 M-79.65 M-104.47 M-121.18 M-150.58 M
DBV Technologies S.A. - American Depositary Shares
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.